No crossover between treatment organizations was allowed before the final analysis of the primary end point. Patients were evaluated every 14 days while receiving treatment and every 8 weeks from the time they halted treatment until their death or the trial cutoff date for data collection. Radiologic assessments of tumors were performed by investigators every 8 weeks, and the Response Evaluation Requirements in Stable Tumors , edition 1.1,16 was used to assess tumor responses. Adverse events were classified and graded based on the National Cancers Institute Common Terminology Criteria for Adverse Events, version 4.03.17 End Points The principal end point was overall survival, that was defined as the right time from randomization to death from any cause.After week 8, individuals returned to the investigational site at least every four weeks or as necessary to assess and adjust the analysis medications . The standard of lifestyle was assessed at baseline and every 12 weeks thereafter before end of treatment. Treatments for individuals assigned to receive the standard of treatment were selected by the investigator on the basis of standard institutional procedures or therapeutic suggestions. Throughout the study, patients in either treatment group could receive additional treatments for immune thrombocytopenia if indeed they were deemed medically required by the investigator. If therapy in either mixed group was considered to be ineffective or connected with severe side effects, investigators could perform a splenectomy.